

## AUROBINDO PHARMA LIMITED (CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India.
Tel: +91 040 23736370 Fax: +91 040 23747340 Email: info@aurobindo.com

## STATEMENT OF STANDALONE / CONSOLIDATED **UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2021**

(Rs. in Lakhs)

er – dang kanadakan kan kanada manada bahan ang kanada manada manada manada manada baha kanada kan kan da mana

Sr. No.		Standalone			Consolidated		
	Particulars	Quarter ended	Year ended	Quarter ended	Quarter ended	Year ended	Quarter ended
		30.06.2021	31.03.2021	30.06.2020	30.06.2021	31.03.2021	30.06.2020
		Unaudited	Audited	Unaudited	Unaudited	Audited	Unaudited
. 1	Total income from operations (net)	2,89,375	15,82,368	3,42,599	5,70,198	24,77,463	5,92,478
2	Net Profit / (Loss) for the period (before Tax and Exceptional items)	33,505	4,19,301	95,056	1,01,771	4,52,902	1,08,435
	Net Profit / (Loss) for the period before tax (after Exceptional items)	33,505	4,19,301	95,056	1,01,771	7,34,360	1,08,435
4	Net Profit / (Loss) for the period after tax (after Exceptional items)	21,507	3,11,291	70,753	76,997	5,33,383	78,316
5	Total Comprehensive income for the period [ Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax)]	21,347	3,10,649	70,440	1,00,130	5,33,857	84,429
6	Paid-up equity Share Capital (face value of Re.1/- each)	5,859	5,859	5,859	5,859	5,859	5,859
	Other equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet		15,86,602			21,87,127	
	Other equity (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	As on March 31, 2021 15,86,602			As on March 31, 2021 21,87,127		
	Earnings per share of Re.1/- each	(not annualised)	(annualised)	(not annualised)	(not annualised)	(annualised)	(not annualised)
	(a) Basic (in Rs.)	3.67	53.13	12.07	13.14	91.04	13.32
	(b) Diluted (in Rs.)	3.67	53.13	12.07	13.14	91.04	13.32

Note: The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchanges' web sites viz. www.bseindia.com, www.nseindia.com and on the Company's web site viz. www.aurobindo.com

> By Order of the Board Aurobindo Pharma Limited

N. Govindarajan Managing Director

Place: Hyderabad Date : 12 August 2021

www.aurobindo.com